SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a combination of factors including its shift to a hybrid infrastructure model with AI GPU hosting, potential short squeeze, and positive sentiment from an ongoing conference. Community members are closely watching for a breakout above key resistance levels, while also acknowledging the risks associated with volatility and dilution. The stock's low float is contributing to significant price swings.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending as investors anticipate earnings, with much of the conversation centered on its potential role in the AI landscape and possible new deals with major tech players like Microsoft. Community members are weighing the potential for a significant post-earnings move, drawing comparisons to both positive and negative reactions from other tech companies like Oracle. Bullish sentiment seems to be fueled by expectations of strong AI revenue growth and the company's existing relationships with Google and Meta.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is surging amid excitement surrounding its affiliate Gemini Titan securing a CFTC license for regulated prediction markets, potentially positioning the company to compete with platforms like Kalshi and Polymarket. Community members are actively discussing the potential for a short squeeze, speculating on price targets and a possible return to IPO levels. Bullish sentiment is fueled by optimism surrounding the new market opportunities and the view that the license significantly undervalues the stock.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is experiencing volatility, driven by recent data showing a slowdown in November trading volumes and a price target adjustment from analysts. The community is actively debating whether the dip presents a buying opportunity or signals further declines, while also discussing the potential impact of Robinhood's expansion into prediction markets and banking services. Some traders express frustration with the stock's price action, citing manipulation and correlation with Bitcoin's movements.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending due to upcoming earnings, with the community actively debating whether the report will catalyze a significant price movement. Some traders are pointing to large options positions as a sign of an impending surge, while others remain cautious, citing broader economic concerns and potential tariff impacts. Bullish investors highlight Lululemon's brand strength, international growth potential, and compelling valuation, while bears express concerns about competition and declining sales.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending ahead of its Autonomy and AI Day, where the company is expected to showcase its in-house software and self-driving technology; community chatter revolves around speculation on potential announcements and comparisons to Tesla's approach, particularly regarding lidar; broader discussion includes debate around Rivian's valuation, production capabilities, and long-term strategy in the competitive EV market.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending down as investors react to concerns over increased spending on AI infrastructure and growing debt, despite a solid backlog. The community is debating whether the drop is an overreaction or a sign of deeper issues, while analysts are trimming their price targets. Some traders are looking for a bottom while others are anticipating a further decline.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending due to a recently announced national retail distribution agreement with Walmart, which is expected to bring its hearing protection products to a wider audience. The community is actively discussing potential short squeezes and debating whether the Walmart news justifies the stock's increased price, while some express concern about potential pullbacks. Analysts' target prices also seem to be fueling conversation around the stock.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending as investors discuss its deepening ties with major defense and aerospace companies, sparking optimism about future contracts and revenue growth. The community is highlighting the company's unique 3D printing capabilities for complex parts and its potential to disrupt traditional manufacturing. Some investors are pointing to a possible short squeeze and comparing the stock's potential to that of $SMX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best-Performing ETFs of November 

November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


Novo Nordisk A/S (NVO) shares slid 3% in the early premarket session on Monday as the Ozempic and Wegovy weight-loss drugmaker snagged a&nbsp;bearish recommendation from a Wall Street firm.&nbsp;Morgan Stanley analyst downgraded&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> to ‘Underweight’ from ‘Equal Weight’ and also reduced the price target for the stock to $47 from $59, the excerpts of the note published by The Fly showed. Morgan Stanley’s updated price target implies a nearly 13% downside from the stock’s Friday close.The stock was among the top five trending equity tickers on Stocktwits early Monday. Retail sentiment toward the stock, however, remained ‘extremely bullish’ (76/100), and the message volume on the stream was ‘high.’<figure class="image"><img style="aspect-ratio:619/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_5_23_05_AM_png_5def6a683f.webp" alt="Screenshot 2025-09-29 at 5.23.05 AM.png" width="619" height="53"><figcaption>NVO sentiment and message volume as of 5:20 a.m. ET, Sept. 29 | source: Stocktwits</figcaption></figure>Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures. According to the firm, this would drive downside revisions to the 2026 and 2027 consensus estimates for Novo Nordisk.&nbsp;Analysts at the firm said the lack of momentum in U.S. prescriptions for Wegovy, Ozempic and Rybelsus makes it cautious on the company's short-term growth profile. Additionally, the analyst noted that the lack of catalysts exacerbates the downside risk profile over the next six months.A New York Times report stated last week that the company was cutting jobs following the profit warning it issued in late July.&nbsp;Novo Nordisk stock has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-analyst-says-i-phone-s-worst-period-in-china-has-passed/chDMvs4R378">Apple Analyst Says ‘iPhone’s Worst Period In China Has Passed’ — The Xiaomi Data That Adds Strength To Bull Case For Cupertino</a>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.

Equity

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.



NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another sales miss for its obesity and diabetes drugs.The company reported Q4&nbsp;earnings per share (EPS) of $5.32, beating the $5.08 consensus estimate, while revenue came in at $13.53 billion, topping Wall Street’s $13.43 billion forecast.&nbsp;Sales of its blockbuster GLP-1 drugs Zepbound and Mounjaro surged but came in slightly below expectations, weighed down by lower realized prices.&nbsp;Mounjaro generated $3.53 billion in revenue, a 60% jump from the prior year but short of analysts’ $3.62 billion estimate. Zepbound posted $1.91 billion in sales, missing the $1.98 billion forecast.&nbsp;This marks the second consecutive quarter where both drugs have fallen short of estimates, according to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html">CNBC</a>.Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.&nbsp;CEO David Ricks called 2024 a highly successful year, highlighting major clinical readouts for tirzepatide in treating chronic diseases tied to obesity, billions in manufacturing expansion, and the launch of Alzheimer’s drug Kisunla and dermatitis medication Ebglyss as key drivers of long-term growth.&nbsp;“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” he added.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Eli_Lilly_sentiment_and_message_volume_Feb_6_premarket_0e4b15d3e8.png" alt="Eli Lilly sentiment and message volume Feb 6 premarket.png" width="1318" height="324"><figcaption>Eli Lilly sentiment and message volume Feb 6 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, Eli Lilly was among the top 10 trending tickers ahead of Thursday’s opening, with sentiment turning more bullish.&nbsp;Optimistic traders pointed to the earnings beat and expected continued strength, with one eyeing a move past $900.&nbsp;<stembedurl>https://stocktwits.com/Zukio/message/603106677</stembedurl>Another said hedge funds and institutional investors would likely drive the&nbsp;actual move during market hours.<stembedurl>https://stocktwits.com/nat9co/message/603108641</stembedurl>For 2025, Eli Lilly expects EPS between $22.50 and $24.00, compared to the $22.69 consensus estimate, and projects revenue between $58 billion and $61 billion, surpassing Wall Street’s $58.91 billion forecast.&nbsp;The company is ramping production to meet soaring demand, estimating it will manufacture at least 1.6 times the number of incretin doses in the first half of 2025 compared to a year ago.&nbsp;Lilly also announced plans to report late-stage data for its next-generation obesity drug retatrutide later this year, ahead of schedule.As of Wednesday’s close, <a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> was up nearly 8% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Roundhill Investments Surpasses $4 Billion AUM Milestone

Roundhill Investments Surpasses $4 Billion AUM Milestone Roundhill Investments Surpasses $4 Billion AUM Milestone PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Roundhill...

Eli Lilly &amp; Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6%&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-falls-on-q4-weight-loss-drug-sales/chG8mwrRVc">plunge</a> — the worst session for the stock in nearly four years.&nbsp;The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance, with significant misses in sales for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.However, several Wall Street analysts expressed optimism, suggesting the dip could offer an attractive entry point for investors.Leerink noted Lilly lowered its Q4 revenue guidance by 5% but issued a 2025 revenue forecast 2% above its consensus, according to The Fly. The brokerage maintained its 'Outperform' rating, citing long-term growth potential and a promising pipeline.BofA Securities reiterated a 'Buy' rating with a $997 price target,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/eli-lilly-bofa-says-buy-the-dip-after-shares-slide-on-q4-miss-3813128">according</a> to Investing.com. Analyst Tim Anderson emphasized that despite short-term challenges, Lilly remains a dominant player in the "diabesity" market with significant growth opportunities.JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity, highlighting Lilly's strong 2025 positioning, expanded market presence, and anticipated 60% growth in sellable doses of incretins in the first half of 2025.Mizuho's Jared Holz&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=eli+lilly+mizuho&amp;oq=eli&amp;gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDsyBggCEEUYOzITCAMQLhiDARjHARixAxjRAxiABDIGCAQQRRg5MgYIBRBFGDwyBggGEEUYPDIGCAcQRRg90gEINjAxMGowajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8">told</a> CNBC that "some of the supply commentary from the company makes a lot of sense" and highlighted the nascent stage of the obesity market. However, he flagged valuation as a concern, with Lilly trading at 32 times 2025 earnings estimates—higher than most large-cap pharma peers.Retail message volume on Stocktwits about Lilly jumped over 240% on Tuesday.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_15_premarket_8c6741e2bb.png" alt="LLY sentiment and message volume Jan 15 premarket.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 15 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>Heading into Wednesday, sentiment on the platform remained 'bullish,' as watchers took cues from analyst optimism and kept faith in long-term prospects for Lilly's weight-loss and diabetes drugs remain intact.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly's stock</a> is down 4.5% year-to-date but has gained over 16% in the past 12 months. The company will report fourth-quarter and full-year results next month.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

Eli Lilly Recovers Premarket As Analysts Defend Stock After Tuesday’s Slide, Retail Bullish

Shares of Eli Lilly &amp; Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the&nbsp;stock’s worst day since March 15, 2021.&nbsp;The decline followed a disappointing fourth-quarter revenue outlook update, particularly from its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.The company now forecasts full-year revenue of about $45 billion, down from its previous range of $45.4 billion-$46 billion and below the consensus of $45.55 billion.&nbsp;Fourth-quarter revenue is expected to be approximately $13.5 billion, falling short of the $13.93 billion consensus.&nbsp;Sales of Mounjaro totaled $3.5 billion, below the $4.4 billion estimate, while Zepbound brought in $1.9 billion, missing expectations of $2.14 billion.CEO David A. Ricks attributed the shortfall to slower-than-expected growth in the U.S. incretin market, compounded by lower year-end channel inventory. Incretins like GLP-1 are used in diabetes and obesity drugs such as Mounjaro and Zepbound.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_14_082f836502.png" alt="LLY sentiment and message volume Jan 14.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 14 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>However, retail sentiment on Stocktwits stayed ‘extremely bullish,’ with the ticker climbing to the top five trending symbols list amid a spike in message volume.&nbsp;Many retail investors considered the dip an overreaction, expressing optimism for 2025 projections and hinting they were buying the dip.<stembedurl>https://stocktwits.com/ChrisH76/message/599965534</stembedurl><stembedurl>https://stocktwits.com/NastyPelosi/message/599965487</stembedurl><stembedurl>https://stocktwits.com/OldFagGuy/message/599960901</stembedurl><stembedurl>https://stocktwits.com/JackCoLu/message/599959582</stembedurl>Lilly expects continued growth for Mounjaro and Zepbound in 2025, supported by expanded manufacturing capacity and new market launches.&nbsp;The company plans to increase production of tirzepatide by at least 60% in the first half of 2025 compared to the same period in 2024.Lilly anticipates revenue contributions from new drugs, including oncology treatment Jaypirca, dermatitis medication Ebglyss, Crohn’s disease therapy Omvoh, and Alzheimer’s drug Kisunla.&nbsp;Additionally, the company is pursuing approvals for new indications of existing medicines and potential launches, such as imlunestrant for metastatic breast cancer.Lilly expects its experimental weight-loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-01-13/lilly-sees-new-weight-loss-pill-approval-in-early-2026-ceo-says?sref&amp;">revealed</a> during an interview with Bloomberg TV at the JPMorgan Healthcare Conference in San Francisco on Monday. Data on the pill is expected by mid-2025.Lilly’s stock has gained over 16% in the past year but is down nearly 5% in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections

The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches.  

Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$34.72
Prev Close	$34.24
Open	$34.56
Dividend Yield	N/A
50-Day Moving Average	$30.23
Beta	N/A
Avg. Volume	16,050.42
PE Ratio	N/A

52-Week High	$34.93
52-Week Low	$20.01
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Latest OZEM News

OZEMRoundhill GLP-1 & Weight Loss ETF